Celebrating 25 years Est 1999-2024
*Across 3 years $2158.56 only $755.50
Announced additional interim data from ongoing Phase 1 clinical study of ORX750, a novel orexin receptor 2...
BOSTON and LONDON, Nov. 04, 2024 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (Nasdaq: CNTA), a...
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.